Tag: FATE

FB Nasdaq FB Facebook
Finance

Biotech Bearish Stocks: Celsus Therapeutics (NASDAQ:CLTX), Reliv International (NASDAQ:RELV), Fate Therapeutics Inc (NASDAQ:FATE), CorMedix Inc. (NYSEMKT:CRMD)

Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) major shareholder Sabby Management, Llc acquired 16,203 shares of Celsus Therapeutics PLC stock in a transaction dated Thursday, March 27th. The shares were purchased at an average price of $6.66 per share, for a total transaction of $107,911.98. Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) stock performance was -5.24% in last session and finished the day at $6.15. Traded volume was 35.9K … Continue reading Biotech Bearish Stocks: Celsus Therapeutics (NASDAQ:CLTX), Reliv International (NASDAQ:RELV), Fate Therapeutics Inc (NASDAQ:FATE), CorMedix Inc. (NYSEMKT:CRMD)

John Meady
Finance

Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Fate Therapeutics Inc (NASDAQ:FATE) recently issued a statement that it has enrolled it first patient for the second phase of this study. The primary aim of the PUMA study is to assess the efficacy and safety of PROHEMA in a randomized, controlled environment for patients that are under treatment for hematopoietic stem cell or HSC transplantation for hematologic malignancies. Fate Therapeutics Inc (NASDAQ:FATE) stock performance … Continue reading Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Colin Pettis
BioTech

Biotech Unusual Volume: Tengion (OTCMKTS:TNGN), Alseres Pharmaceuticals (OTCMKTS:ALSE), Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN)

Tengion, Inc. (OTCMKTS:TNGN) on Mar. 3 issued notices to the holders (the “2012 Investors”) of senior secured notes issued on October 2, 2012 and to the holders (the “2013 Investors” and together with the 2012 Investors, the “Investors” and each, an “Investor”) of senior secured notes issued on June 28, 2013 stating that the Company plans to issue shares of common stock, $0.001 par value … Continue reading Biotech Unusual Volume: Tengion (OTCMKTS:TNGN), Alseres Pharmaceuticals (OTCMKTS:ALSE), Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN)

Colin Pettis
BioTech

Biotech Stocks New Highs: Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN), Celladon Corp (NASDAQ:CLDN), Kindred Biosciences (NASDAQ:KIN)

Fate Therapeutics, Inc. (NASDAQ:FATE) announced that it has enrolled the first patient in its phase II study (PUMA − P rohema in UM bilical cord blood transplant in A dults) on Prohema. Fate Therapeutics Inc. (NASDAQ:FATE) stock performance was 27.14% in last session and finished the day at $11.15. Traded volume was 295,227.00 shares in the last session and the average volume of the stock … Continue reading Biotech Stocks New Highs: Fate Therapeutics (NASDAQ:FATE), Synthetic Biologics (NYSEMKT:SYN), Celladon Corp (NASDAQ:CLDN), Kindred Biosciences (NASDAQ:KIN)

Colin Pettis